1.28
price up icon1.59%   0.02
after-market アフターアワーズ: 1.30 0.02 +1.56%
loading
前日終値:
$1.26
開ける:
$1.29
24時間の取引高:
2.91M
Relative Volume:
0.91
時価総額:
$319.35M
収益:
$95,000
当期純損益:
$-327.27M
株価収益率:
-0.6038
EPS:
-2.12
ネットキャッシュフロー:
$-239.25M
1週間 パフォーマンス:
+7.56%
1か月 パフォーマンス:
-11.72%
6か月 パフォーマンス:
-37.71%
1年 パフォーマンス:
-52.24%
1日の値動き範囲:
Value
$1.255
$1.33
1週間の範囲:
Value
$1.13
$1.33
52週間の値動き範囲:
Value
$0.8621
$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
名前
Allogene Therapeutics Inc
Name
セクター
Healthcare (1164)
Name
電話
(650) 457-2700
Name
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
職員
361
Name
Twitter
@AllogeneTx
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
ALLO's Discussions on Twitter

ALLO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.28 319.35M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.85 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
314.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.24 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
250.30 28.51B 3.81B -644.79M -669.77M -6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-14 ダウングレード Citizens JMP Mkt Outperform → Mkt Perform
2025-03-14 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 再開されました Oppenheimer Outperform
2024-05-31 開始されました Piper Sandler Overweight
2024-01-05 ダウングレード Guggenheim Buy → Neutral
2024-01-05 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 開始されました Citigroup Buy
2023-06-26 再開されました Oppenheimer Outperform
2023-03-21 開始されました Bernstein Mkt Perform
2023-01-24 アップグレード JP Morgan Neutral → Overweight
2023-01-06 アップグレード Robert W. Baird Neutral → Outperform
2022-12-12 ダウングレード BofA Securities Buy → Underperform
2022-08-10 ダウングレード Raymond James Outperform → Mkt Perform
2022-07-15 アップグレード Goldman Neutral → Buy
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-28 繰り返されました B. Riley Securities Buy
2021-10-20 開始されました Cowen Outperform
2021-10-08 ダウングレード Goldman Buy → Neutral
2021-10-08 ダウングレード Stifel Buy → Hold
2021-09-23 アップグレード Raymond James Mkt Perform → Outperform
2021-06-21 再開されました Jefferies Buy
2021-05-20 アップグレード Truist Hold → Buy
2021-05-14 開始されました B. Riley Securities Buy
2021-01-26 アップグレード Stifel Hold → Buy
2020-12-10 再開されました H.C. Wainwright Buy
2020-11-24 開始されました BofA Securities Buy
2020-10-23 開始されました RBC Capital Mkts Outperform
2020-06-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-29 繰り返されました H.C. Wainwright Buy
2020-05-19 アップグレード ROTH Capital Neutral → Buy
2020-05-15 アップグレード Guggenheim Neutral → Buy
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-05-14 ダウングレード SunTrust Buy → Hold
2020-04-13 開始されました SunTrust Buy
2020-03-13 開始されました H.C. Wainwright Buy
2020-03-05 開始されました Stifel Hold
2020-02-24 開始されました Berenberg Hold
2019-12-18 開始されました JMP Securities Mkt Outperform
2019-11-04 開始されました Canaccord Genuity Buy
2019-08-09 開始されました BTIG Research Buy
2019-06-05 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Neutral
2019-05-23 開始されました Stifel Hold
2019-03-29 開始されました Piper Jaffray Overweight
すべてを表示

Allogene Therapeutics Inc (ALLO) 最新ニュース

pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 14, 2025

Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data By Investing.com - Investing.com India

Jun 14, 2025
pulisher
Jun 14, 2025

Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Allogene's SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Insider Sell: Deborah Messemer Sells 36,885 Shares of Allogene T - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025
pulisher
Jun 12, 2025

Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now - simplywall.st

Jun 12, 2025
pulisher
Jun 04, 2025

Allogene Therapeutics at Jefferies Conference: Delays and Optimism By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Allogene Therapeutic's ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma - CRISPR Medicine News

Jun 04, 2025
pulisher
Jun 03, 2025

Allogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell Carcinoma - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

Citi maintains buy rating on Allogene stock following ASCO data - Investing.com Australia

Jun 03, 2025
pulisher
Jun 02, 2025

Citi maintains buy rating on Allogene stock following ASCO data By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics (ALLO) Showcases Promising Data from Phase 1 TRAVERSE Study | ALLO Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - The Manila Times

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025 - Nasdaq

Jun 01, 2025
pulisher
Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO - MarketScreener

Jun 01, 2025
pulisher
May 29, 2025

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha

May 29, 2025
pulisher
May 28, 2025

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

May 28, 2025
pulisher
May 28, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

May 28, 2025
pulisher
May 27, 2025

Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy - Investing.com Canada

May 27, 2025
pulisher
May 26, 2025

Allogene Therapeutics’s SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com

May 26, 2025
pulisher
May 24, 2025

Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Merus (MRUS) - The Globe and Mail

May 24, 2025
pulisher
May 23, 2025

Allogene Therapeutics Announces Participation in Upcoming Invest - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times

May 23, 2025
pulisher
May 23, 2025

Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Allogene shares update on CAR T-cell therapies at ASCO meeting - Investing.com Australia

May 23, 2025
pulisher
May 22, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication F - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - The Manila Times

May 22, 2025
pulisher
May 22, 2025

Allogene shares update on CAR T-cell therapies at ASCO meeting By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

Allogene Therapeutics Announces Upcoming Presentations at ASCO 2025 Featuring ALLO-316 and ALPHA3 Trial Data - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st

May 22, 2025
pulisher
May 22, 2025

Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN

May 22, 2025
pulisher
May 21, 2025

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com

May 21, 2025
pulisher
May 17, 2025

Citigroup Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock Price - Defense World

May 17, 2025
pulisher
May 16, 2025

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive

May 16, 2025
pulisher
May 15, 2025

Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - GuruFocus

May 15, 2025
pulisher
May 15, 2025

ALLO: Citigroup Lowers Price Target But Maintains Buy Rating | A - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

May 15, 2025

Allogene Therapeutics Inc (ALLO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.40
price down icon 2.10%
$35.84
price down icon 0.78%
$25.00
price down icon 3.40%
$98.18
price up icon 1.57%
$112.89
price down icon 0.90%
biotechnology ONC
$250.30
price down icon 1.22%
大文字化:     |  ボリューム (24 時間):